Since the PPIG mutation we identified in vivo is expected to be a gain-of-function mutation, the knockdown of PPIG in the HCT116 cell line in vitro should lead to the reverse of the downstream effects of PPIG mutation in the cancer cells of Patient CRC05 in vivo (Here, we only considered AS events with a PSI difference greater than 5%, without requiring statistical significance). Here, PPIG is linked to cancer.